Who Finances Europe’s Industrial Scaleup?
Five investors, different mandates, a shared financing challenge.
EQT’s appointment to manage the Scaleup Europe Fund settled who would lead the vehicle. Europe’s industrial financing challenge remains broader. Atomico, Eurazeo, Vitruvian Partners and Northzone bring different investment capabilities, and some already invest alongside the fund. The next test is how these investors can help promising technologies reach commercial scale while building lasting European capacity.
Six questions connect the original candidates’ investment approaches with the practical requirements of industrial expansion: capital, customers, production capacity and time.
🟦 Was EQT a reasonable choice for the mandate?
There is a clear institutional rationale. The Commission identifies EQT’s experience in growth and technology investing, European anchoring, fundraising capacity and ability to manage a vehicle of this scale as the grounds for its selection. The fund targets approximately €5 billion, anchored by a €1 billion Commission contribution, although that target must remain distinct from capital formally committed.
Those capabilities matter when attracting pension funds and other institutions to European growth technology. They provide a foundation for assembling substantial investment rounds.
The next test concerns deployment: which financing constraints does that capital overcome, and what can the supported companies consequently achieve? Fundraising strength establishes capacity. Investment outcomes must demonstrate its value.
🟦 What happened to the other candidates?
The original competition brought together EQT, Atomico, Eurazeo, Vitruvian Partners and Northzone. According to Sifted’s reporting, EQT and Atomico reached the final stage after the other three were no longer in contention. Two former candidates are now investing alongside the selected manager’s fund.
Atomico joined Bessemer Venture Partners and the Scaleup Europe Fund in co-leading The Exploration Company’s $450 million Series C, announced in September. The financing supports development of the Nyx reusable spacecraft and Storm rocket engine.
Northzone participated in Tandem Health’s $100 million Series B, led by the Scaleup Europe Fund, to support the expansion of its healthcare AI platform. Both figures describe complete company financing rounds, rather than individual investors’ contributions.
These transactions provide concrete examples of cooperation. Their significance depends on whether the combined capital and expertise help companies execute larger programmes, reach customers or sustain development through the next milestone.
🟦 Why do Eurazeo’s and Vitruvian’s strategies matter?
They bring additional perspectives on how businesses grow and how that growth is financed.
Eurazeo’s PME V fund reached a first closing above €1 billion in May, targeting European mid-market technology and services businesses. Separately, its Transition Infrastructure Fund backed terralayr’s German battery-storage expansion. These activities involve different investment strategies, assets and risk assessments.
Vitruvian’s approach spans growth capital, growth buyouts and majority and minority investments. Its international platform includes supporting European businesses as they expand globally.
These distinctions become important as technology companies build production assets, acquire businesses or develop predictable revenues. Assessing an unproven process requires different evidence from financing equipment or an operating facility with contracted income.
Venture, growth, buyout and infrastructure strategies can therefore address different parts of the expansion journey. Each retains its own mandate. The question is where suitable financing becomes available—and where a company’s needs still fall between those mandates.
🟦 What would make more industrial deep tech investable?
Consider a hypothetical advanced-materials producer. It has promising laboratory results and interested customers, but needs a demonstration plant before those customers will commit to buying its output.
An investor faces several connected uncertainties: whether the process will work at scale, what the installation will cost, when customers will qualify the product and how long the company can operate before meaningful revenues arrive.
A workable package might combine company equity, demonstration support, equipment finance and customer commitments. But each element has conditions. Equipment finance still requires a credible repayment route. Customer interest must become a sufficiently reliable commercial commitment. Public support needs a defined purpose and an appropriate allocation of risk.
The practical task is to identify the next commercially meaningful milestone, calculate its full funding requirement and establish who can carry the remaining risks.
A larger round helps only if its structure and duration match that task.
🟦 How can the EIC and investors improve the transition?
The Commission states that the Scaleup Europe Fund has no mandatory linkage to the EIC portfolio. EQT makes investment decisions independently on commercial grounds. Prior EIC support therefore provides neither an automatic investment entitlement nor a guarantee of progression.
That independence can coexist with better preparation.
A technology can meet the milestones of a publicly supported project while its next development phase remains outside a private fund’s risk appetite or investment horizon. Identifying that mismatch earlier would give companies more time to assemble a suitable financing route.
The EIC could identify recurring obstacles among businesses approaching industrial scale. EQT, Atomico, Eurazeo, Vitruvian, Northzone and other investors could explain what evidence their respective strategies require.
Industrial customers also have a role: qualification programmes, purchase commitments and deployment partnerships can help clarify demand.
Closer dialogue should make requirements and responsibilities clearer while preserving independent selection.
🟦 What would demonstrate that cooperation works?
Investment announcements provide a starting point. The stronger evidence comes from what follows.
At company level, useful measures include technical milestones reached, production capacity commissioned, commercial orders secured and sufficient funding to complete the next phase. European value also concerns retained research, critical intellectual property, dependable production access and meaningful governance rights.
At fund level, reporting should distinguish investment counts from capital allocation, and fresh company financing from purchases of existing shares. Each transaction can serve a purpose, but its contribution needs to be explained.
The wider test is whether commercially credible companies encounter fewer avoidable interruptions between development, demonstration and deployment. More investors around the table become consequential when their participation changes what a company can deliver.
Signal
EQT’s mandate gives Europe’s scaleup ambition a focal point. Atomico, Eurazeo, Vitruvian Partners and Northzone remain relevant through their own strategies and, in some cases, direct investment alongside the fund.
Their contribution should be judged against the financing needs of companies approaching commercial scale: the equity required, the assets to be built, the customers prepared to commit and the time needed to reach dependable revenues.
Can Europe assemble the right combination of capital and commercial commitments before promising companies exhaust their financial runway—and who will carry the risks that remain?
Image credit
AI-generated illustration by OpenAI for Altair Media Europe.
Caption
Five investors, different mandates: connecting capital, customers and production capacity to finance Europe’s next generation of industrial technology.
